There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...

Metered-dose inhaler propellants have contributed a rising amount to greenhouse gases in the U.S. Emissions per inhaler declined slightly over the past decade, but an increase in annual prescription ...

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic obstructive ...

MIAMI (August 20, 2024) – Inhaler misuse leading to inadequate medication delivery impacts a person’s ability to manage symptoms of chronic obstructive pulmonary disease (COPD), and additional ...

Misunderstanding COPD and asthma can be risky. Recognising the difference in the condition, treatment options, and the need for early intervention is important.

Approximately two thirds of hospitalized adults with chronic obstructive pulmonary disease (COPD) received suboptimal treatment with inhalers, mainly resulting from errors, based on data from 96 ...

Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterized by loss of lung elasticity, which leads to dysfunctional gaseous exchange. COPD is the third leading cause of ...